MedTrace Logo

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

NCT01403025 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4121

Last updated 2018-02-12

No results posted yet for this study

Summary

This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).

Conditions

Interventions

DRUG

liraglutide

Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-19
Primary Completion
2015-12-28
Completion
2015-12-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01403025 on ClinicalTrials.gov